Metabolic · FDA Approved
Lixisenatide (Adlyxin)
FDA-approved
01 · Overview
A selective GLP-1 receptor agonist derived from exendin-4 with a modified C-terminal tail containing six lysine residues. Lixisenatide increases glucose-dependent insulin release, reduces glucagon release, delays gastric emptying and increases satiety; because of its shorter half-life and gastric emptying effect, it may lower postprandial glucose more than other agents in the class (PMID 28133970).
It is given once daily for type 2 diabetes, including as an add-on to basal insulin.
02 · Research summary & key findings
FDA-approved in 2016 for type 2 diabetes. In the GetGoal clinical trial program, lixisenatide reduced HbA1c by 0.6% to 1% and body weight by 0.2 to about 3 kg (PMID 28133970). The ELIXA cardiovascular outcomes trial in patients with a recent acute coronary syndrome showed noninferiority to placebo but no reduction in major cardiovascular events (PMID 26630143). Also available as a fixed-ratio combination with insulin glargine (Soliqua 100/33).
03 · Regulatory status
Lixisenatide (Adlyxin) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Lixisenatide (Adlyxin) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Lixisenatide (Adlyxin) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection (daily)
References
- [1]Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome N Engl J Med, 2015. PMID 26630143
- [2]Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management Ann Pharmacother, 2017. PMID 28133970
Primary literature
- PubMed: "Lixisenatide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Lixisenatide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Lixisenatide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.